SV2003001515A - Hidrato estable de un antagonista de receptores muscarinicos. pc22018 - Google Patents

Hidrato estable de un antagonista de receptores muscarinicos. pc22018

Info

Publication number
SV2003001515A
SV2003001515A SV2003001515A SV2003001515A SV2003001515A SV 2003001515 A SV2003001515 A SV 2003001515A SV 2003001515 A SV2003001515 A SV 2003001515A SV 2003001515 A SV2003001515 A SV 2003001515A SV 2003001515 A SV2003001515 A SV 2003001515A
Authority
SV
El Salvador
Prior art keywords
synthro
urbanity
bladder
antagonist
muscarinic receptors
Prior art date
Application number
SV2003001515A
Other languages
English (en)
Inventor
Peter James Dunn
John George Matthews
Trevor Jack Newbury
Connor Garry O
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9933731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SV2003001515(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of SV2003001515A publication Critical patent/SV2003001515A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

UN HIDRATO SOLIDO ESTABLE DE UN ANTAGONISTA DE RECEPTORES MUSCARINICOS ES UTIL EN EL TRATAMIENTO DE SINDROME DE INTESTINO IRRITABLE, ENFERMEDAD DIVERTICULAR, ACALASIA ESOFAGICA, ENFERMEDAD OBSTRUCTIVA CRONICA DE LAS VIAS RESPIRATORIAS, VEJIGA HIPERACTIVA (QUE INCLUYE LOS SINTOMAS DE INCONTINENCIA, URGENCIA Y FRECUENCIA), INCONTINENCIA URINARIA, URGENCIA URINARIA NEUROGENICA O POLAQUIURIA , TRATAMIENTO DEL TRASTORNO FUNCIONAL DE LA VEJIGA , PERDIDA DE ORINA, DOLOR O DIFICULTAD DE LA MICCION CAUSADA POR LA VEJIGA NEUROGENICA, VEJIGA ESPASTICA O HIPERTONICA, SINDROME DE VEJIGA DISFUNCIONAL, TRASTORNOS GASTROINTESTINALES QUE INCLUYEN HIPERACTIVIDAD GASTROINTESTINAL , Y EFECTO RELAJANTE EN LAS CELULAS DEL MUSCULO LISO INTESTINAL.
SV2003001515A 2002-03-26 2003-03-25 Hidrato estable de un antagonista de receptores muscarinicos. pc22018 SV2003001515A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0207104.1A GB0207104D0 (en) 2002-03-26 2002-03-26 Stable hydrate of a muscarinic receptor antagonist

Publications (1)

Publication Number Publication Date
SV2003001515A true SV2003001515A (es) 2003-12-15

Family

ID=9933731

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2003001515A SV2003001515A (es) 2002-03-26 2003-03-25 Hidrato estable de un antagonista de receptores muscarinicos. pc22018

Country Status (23)

Country Link
US (3) US6930188B2 (es)
EP (2) EP2336124B1 (es)
JP (2) JP2005524678A (es)
KR (4) KR20100101182A (es)
CN (1) CN100345840C (es)
AR (1) AR042608A1 (es)
AT (1) ATE495169T1 (es)
AU (1) AU2003209921A1 (es)
BR (2) BRPI0308706B8 (es)
CA (1) CA2480287C (es)
CY (2) CY1111200T1 (es)
DE (1) DE60335711D1 (es)
DK (2) DK1490357T3 (es)
ES (2) ES2358644T3 (es)
GB (1) GB0207104D0 (es)
HK (2) HK1080847A1 (es)
PA (1) PA8569701A1 (es)
PT (2) PT2336124E (es)
SI (2) SI2336124T1 (es)
SV (1) SV2003001515A (es)
TW (1) TW200306816A (es)
UY (1) UY27735A1 (es)
WO (1) WO2003080599A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0207104D0 (en) * 2002-03-26 2002-05-08 Pfizer Ltd Stable hydrate of a muscarinic receptor antagonist
US7244765B2 (en) * 2004-06-25 2007-07-17 Cytokine Pharmasciences, Inc Guanylhydrazone salts, compositions, processes of making and methods of using
BRPI0609952A2 (pt) * 2005-04-24 2010-05-11 Wyeth Corp métodos para modular a função da bexiga
CA2630478A1 (en) 2005-12-27 2007-07-05 Teva Pharmaceutical Industries, Ltd Processes for preparing darifenacin hydrobromide
EP2109601A2 (en) * 2007-01-05 2009-10-21 Dr. Reddy's Laboratories Ltd. Preparation of darifenacin and its salts
CA2675942C (en) * 2007-02-23 2016-04-12 Theravance, Inc. Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists
US20090005309A1 (en) * 2007-05-18 2009-01-01 Auspex Pharmaceuticals, Inc. Substituted piperidines
WO2009007853A2 (en) * 2007-06-08 2009-01-15 Actavis Group Ptc Ehf Novel polymorphs of darifenacin free base and its hydrobromide salt
US20090005431A1 (en) * 2007-06-30 2009-01-01 Auspex Pharmaceuticals, Inc. Substituted pyrrolidines
US20090018346A1 (en) * 2007-07-13 2009-01-15 Medichem, S.A. Amorphous Form Of Darifenacin Hydrobromide And Processes For The Preparation Thereof
CZ300895B6 (cs) * 2008-01-28 2009-09-02 Zentiva, A. S. Zpusob prípravy Darifenacinu
WO2009125426A2 (en) * 2008-02-08 2009-10-15 Neuland Laboratories Ltd NOVEL PROCESS FOR THE PREPARATION OF (3SM-[2-(2 J-DIHYDRO-5- BENZOFURANYLϊETHYL]-α.α -DIPHENYL-3-PYRROLIDINEACETAMIDE HYDROBROMIDE
JP5450387B2 (ja) 2008-04-02 2014-03-26 株式会社カネカ （ｓ）−３−（１−シアノ−１，１−ジフェニルメチル）−ピロリジンの製造法
WO2010032225A2 (en) * 2008-09-22 2010-03-25 Watson Pharma Private Limited Process for preparation of darifenacin and intermediates used in the process
EP2236509A1 (en) 2009-04-01 2010-10-06 Ragactives, S.L. Method for obtaining 1,3-difunctionalized pyrrolidine derivatives
WO2011070419A1 (en) 2009-12-10 2011-06-16 Aurobindo Pharma Limited An improved process for the preparation of darifenacin hydrobromide
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
AU2016371762A1 (en) * 2015-12-14 2018-06-21 Cyclerion Therapeutics, Inc. Use of sGC stimulators for the treatment of gastrointestinal sphincter dysfunction
CN109641822B (zh) * 2016-08-12 2022-03-11 拜耳作物科学股份公司 制备取代苯乙烯衍生物的方法
JP7285259B2 (ja) * 2017-09-12 2023-06-01 エルテーエス ローマン テラピー－ジステーメ アーゲー イオントフォレーシス用マイクロニードルデバイス

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5233053A (en) * 1989-03-17 1993-08-03 Pfizer Inc. Pyrrolidine derivatives
GB8906166D0 (en) 1989-03-17 1989-05-04 Pfizer Ltd Therapeutic agents
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9400600D0 (en) 1994-01-14 1994-03-09 Pfizer Ltd Treatment of motion seckness
GB9518953D0 (en) * 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
GB9612710D0 (en) * 1996-06-18 1996-08-21 Pfizer Ltd Method of treatment
JP2001502302A (ja) * 1996-09-19 2001-02-20 アメリカン・ホーム・プロダクツ・コーポレイション 尿失禁を治療する方法
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
GB0207104D0 (en) * 2002-03-26 2002-05-08 Pfizer Ltd Stable hydrate of a muscarinic receptor antagonist

Also Published As

Publication number Publication date
KR20100101182A (ko) 2010-09-16
US7696357B2 (en) 2010-04-13
CN1642945A (zh) 2005-07-20
UY27735A1 (es) 2003-10-31
TW200306816A (en) 2003-12-01
GB0207104D0 (en) 2002-05-08
PT1490357E (pt) 2011-03-01
EP2336124A1 (en) 2011-06-22
US6930188B2 (en) 2005-08-16
DK1490357T3 (da) 2011-04-04
BR122018000397B1 (pt) 2019-07-02
AR042608A1 (es) 2005-06-29
KR101026283B1 (ko) 2011-03-31
DK2336124T3 (da) 2012-12-17
AU2003209921A1 (en) 2003-10-08
US20030191176A1 (en) 2003-10-09
PA8569701A1 (es) 2003-12-10
KR20120098888A (ko) 2012-09-05
SI2336124T1 (sl) 2012-12-31
CA2480287A1 (en) 2003-10-02
US20050245597A1 (en) 2005-11-03
CA2480287C (en) 2011-05-31
ES2358644T3 (es) 2011-05-12
WO2003080599A1 (en) 2003-10-02
PT2336124E (pt) 2012-12-12
US20080167367A1 (en) 2008-07-10
HK1080847A1 (en) 2006-05-04
JP2005524678A (ja) 2005-08-18
KR20040093477A (ko) 2004-11-05
DE60335711D1 (de) 2011-02-24
EP1490357A1 (en) 2004-12-29
CY1111200T1 (el) 2015-06-11
CY1113433T1 (el) 2016-06-22
EP2336124B1 (en) 2012-08-29
EP1490357B1 (en) 2011-01-12
KR20110130539A (ko) 2011-12-05
CN100345840C (zh) 2007-10-31
ES2394067T3 (es) 2013-01-16
BRPI0308706B8 (pt) 2021-05-25
JP2010195828A (ja) 2010-09-09
BRPI0308706B1 (pt) 2018-07-10
BR0308706A (pt) 2005-01-04
KR101212908B1 (ko) 2012-12-14
SI1490357T1 (sl) 2011-05-31
HK1156626A1 (en) 2012-06-15
ATE495169T1 (de) 2011-01-15
BR122018000397B8 (pt) 2021-07-27

Similar Documents

Publication Publication Date Title
SV2003001515A (es) Hidrato estable de un antagonista de receptores muscarinicos. pc22018
NO20054959D0 (no) Fremgangsmater for behandling av interleukin-6 relaterte sykdommer
SV2006002245A (es) 2-anilinopirimidinas sustituidas como inhibidores de la quinasa del ciclo celular o del receptor de la tirosina quinasa, su preparacion y su uso como medicamentos ref. p-sv-78.797/msu
EA200900796A1 (ru) Пиперидиновые агонисты gpcr
EA200900880A1 (ru) Пиперидиновые агонисты gpcr
NZ595262A (en) Use of il-23 and il-27 antagonists to treat autoimmune ocular inflammatory disease
BRPI0602589A (pt) bainha aperfeiçoada para uso interno
CY1108480T1 (el) Ανταγωνιστες κιμ-1 και χρηση για την τροποποιηση του ανοσιακου συστηματος
NO20080052L (no) G-Protein kopplede reseptoragonister
DK1280531T3 (da) Formulering bestående af phentolaminmesylat og anvendelse heraf
DK1835924T3 (da) Behandling af parkinsons sygdom og beslægtede sygdomme under anvendelse af postpartum opnåede celler
AR008293A1 (es) Composicion que comprende una cantidad antihistaminica para el tratamiento de las respuestas alergicas de las vias respiratorias superiores
Siracusa et al. Pelvic floor considerations in COVID-19
EP2535330A3 (en) Iminopyridine derivative and use thereof
Butris et al. Sleep disruption in older surgical patients and its important implications
UY26627A1 (es) Antagonistas de receptores de il-8
DOP2003000615A (es) Hidrato estable de un antagonista de receptores muscarinicos
ATE375146T1 (de) Schleimdrogenbasierte lutschtablette gegen entzündliche erkrankungen des mund- und rachenraums
DK1965800T3 (da) Piperidin-derivater til anvendelse i behandling af inkontinenser
FR2857262B1 (fr) Utilisation de la citrulline dans le cadre de l'insuffisance intestinale
EA200400639A1 (ru) Фармацевтическая комбинация агонистов аденозиновых a-2a и бета-2-адренергических рецепторов
UY27564A1 (es) Combinación farmacéutica.
TH79776A (es)
Elliott Orgasmic and ejaculatory problems in clinical practice
AR058438A1 (es) Utilizacion de la gonadotrofina corionica humana por via oral para el tratamiento del sobrepeso (obesidad) asociado a hipertension arterial, diabetes no insulino dependiente, hipercolesterolemia, dislipemias y lipodistrofias

Legal Events

Date Code Title Description
FD Lapse